TRK-IN-30

• Description:

  TRK-IN-30 (Compound C11) is the inhibitor for tropomyosin receptor kinase (TRK) that inhibits TRKA, TRKB and TRKC and drug resistant mutant TRKAG595R with an IC50 of 1.8, 0.98, 3.8, and 54 nM, respectively. TRK-IN-30 inhibits the activation of the downstream PI3K/AKT and MEK/ERK signaling pathways. TRK-IN-30 inhibits the colony formation and cell migration of Km-12, arrests the cell cycle at G0/G1 phase, and induces apoptosis in Km-12[1].

• UNSPSC:

  12352211

• Target:

  Trk Receptor

• Related Pathways:

  Neuronal Signaling; Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Smiles:

  NC1=C(C(NC2=CC(OC)=C(OC)C=C2)=O)C=CC=C1NC3=CC(NC=C4C#N)=C4C=C3

• Molecular Formula:

  C24H21N5O3

• Molecular Weight:

  427.46

• References & Citations:

  [1]Xu S, et al., Design, synthesis and biological evaluation of novel 1H-indole-3-carbonitrile derivatives as potent TRK Inhibitors. Eur J Med Chem. 2025 Jan 3;285:117231.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported